Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug study aims to transform treatment for rare blood disorder

NCT ID NCT06931691

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study is observing how a drug called iptacopan affects the management and outcomes of a rare blood disease called paroxysmal nocturnal hemoglobinuria (PNH) in real-world medical settings in China. It will enroll 80 adult patients who are starting iptacopan treatment, either as their first therapy or after switching from another drug. The main goal is to see how the treatment changes blood health markers, reduces symptoms, and affects patients' use of healthcare resources like hospital visits.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Novartis Investigative Site

    RECRUITING

    Guangzhou, Guangdong, 510000, China

  • Novartis Investigative Site

    RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • Novartis Investigative Site

    RECRUITING

    Zhengzhou, Henan, 450008, China

  • Novartis Investigative Site

    RECRUITING

    Wuhan, Hubei, 430030, China

  • Novartis Investigative Site

    RECRUITING

    Nanchang, Jiangxi, 330006, China

  • Novartis Investigative Site

    RECRUITING

    Changchun, Jilin, 130021, China

  • Novartis Investigative Site

    RECRUITING

    Tianjin, 300020, China

  • Novartis Investigative Site

    RECRUITING

    Tianjin, 300052, China

  • Novartis Investigative Site

    RECRUITING

    Wuhan, 430022, China

Conditions

Explore the condition pages connected to this study.

PAROXYSMAL NOCTURNAL HEMOGLOBINURIA